FDA approves Infilbray, first drug for neurological symptoms of Type 3 Gaucher disease
The agency's release lists gastrointestinal symptoms and mood effects as the most frequent side effects and says serious psychiatric risks, including suicidal ideation and behavior, have been reported.
Key takeaways
- The FDA approved Infilbray (venglustat) tablets on Nov. 18, 2026 as the first treatment for the neurological symptoms of Type 3 Gaucher disease.
- The approval covers adults and pediatric patients who weigh at least 15 kg, about 33 pounds.
- The supporting study enrolled 43 patients aged 12 years and older and compared once-daily oral Infilbray with intravenous enzyme replacement therapy over 52 weeks.
- The FDA release says serious psychiatric risks, including suicidal ideation and behavior, have been reported with the drug.
- For crews: the FDA release lists gastrointestinal symptoms and adverse effects on mood as the most frequently reported side effects of Infilbray.
The U.S. Food and Drug Administration approved Infilbray (venglustat) tablets on Nov. 18, 2026, calling it the first treatment for the neurological symptoms of Type 3 Gaucher disease, according to an FDA news release issued that day [1]. The approval covers adults and children who weigh at least 15 kg, about 33 pounds [1].
The agency granted the approval to Genzyme Corporation, a Sanofi Company [1]. The release says the drug crosses the blood-brain barrier and reduces the buildup of harmful substances in the body and the brain [1].
Acting FDA Commissioner Kyle Diamantas said in the release that the drug "can get to the source of the buildup driving the neurological symptoms" [1].
What the records show
The FDA describes Type 3 Gaucher disease, or GD3, as a rare, inherited condition. A deficient or malfunctioning enzyme leaves the body unable to break down fatty substances called glucosphingolipids, the release says [1]. Those substances collect in organs, tissues and the brain [1].
According to the release, GD3 differs from type 1 Gaucher disease because it also affects the brain and nervous system [1]. The agency lists problems with balance, coordination, speech, memory and thinking, and says these symptoms can worsen progressively [1].
The FDA identifies Infilbray as a glucosylceramide synthase inhibitor [1].
The approval rests on data from a single clinical study described in the release [1]. The details the agency gives are:
- Design: randomized, double-blind and multicenter [1].
- Size: 43 patients with GD3 [1].
- Ages: 12 years and older [1].
- Prior care: all had been treated with enzyme replacement therapy and had reached systemic disease stabilization [1].
- Arms: Infilbray by mouth once daily, or intravenous enzyme replacement therapy every two weeks [1].
- Duration: 52 weeks [1].
Effectiveness was judged with two assessments of neurological symptoms, including those tied to ataxia and to cognitive function, the release says [1]. The FDA defines ataxia in the release as "loss of muscle control and coordination" [1].
At Week 52, patients on Infilbray showed improvement on a measure combining both assessments when compared with patients on enzyme replacement therapy, according to the agency [1].
On safety, the release says the most frequently reported side effects include gastrointestinal symptoms and adverse effects on mood [1]. It also states: "Serious psychiatric risks, including suicidal ideation and behavior, have been reported" [1].
Animal studies pointed to further potential risks, the FDA says. These are potential clouding of vision in younger patients and adverse effects on fetal development when the drug is taken during pregnancy [1].
Infilbray received Orphan Drug designation and Priority Review, according to the release [1].
Why it matters for clinicians
The FDA release describes Infilbray as the first approved treatment aimed at the neurological symptoms of GD3 [1]. In the supporting study, the comparison arm received enzyme replacement therapy, which the release describes as treatment for the non-neurologic manifestations of the disease [1].
The route of administration differs between the two study arms. Infilbray is a tablet taken once daily, while the enzyme replacement therapy in the study was given intravenously every two weeks [1].
The safety findings touch areas that emergency and prehospital clinicians encounter. The release names mood effects among the most frequent side effects and reports serious psychiatric risks, including suicidal ideation and behavior [1]. The approved population includes pediatric patients who weigh at least 15 kg [1].
The underlying disease also carries neurological features that clinicians may see in these patients, including trouble with balance, coordination, speech, memory and thinking, according to the FDA description [1].
What the records do not tell us
The release leaves several points open.
- It gives no numerical results. The size of the improvement at Week 52 is not stated, and the release does not name the two assessments [1].
- It does not say how many patients were assigned to each study arm [1].
- The study enrolled patients aged 12 years and older, while the approval extends to pediatric patients weighing at least 15 kg. The release does not describe the data supporting use in younger or smaller children [1].
- It gives no rates for gastrointestinal effects, mood effects, or suicidal ideation and behavior, and does not say how many study participants were affected [1].
- It does not state the tablet strengths, the dose, or any monitoring requirements [1].
- It does not say whether the labeling carries a boxed warning or contraindications [1].
- It does not say whether patients would take Infilbray alongside enzyme replacement therapy or in place of it [1].
- It gives no price, launch date or availability information, and includes no statement from the company [1].
- It does not say how many people in the United States have GD3 [1].
The FDA says further detail on side effects is in the drug labeling, which the release does not reproduce [1].
Questions readers ask
What is Infilbray approved to treat?
The FDA approved Infilbray (venglustat) tablets for the neurological symptoms of Type 3 Gaucher disease in adults and pediatric patients weighing at least 15 kg, about 33 pounds. The agency calls it the first treatment for those symptoms.
What are the side effects of Infilbray?
The FDA release says the most frequently reported side effects include gastrointestinal symptoms and adverse effects on mood. It also says serious psychiatric risks, including suicidal ideation and behavior, have been reported, and that animal studies pointed to potential clouding of vision in younger patients and adverse effects on fetal development.
What study supported the FDA approval of venglustat?
The FDA cites a randomized, double-blind, multicenter study of 43 patients aged 12 years and older with Type 3 Gaucher disease. Participants took Infilbray once daily or received intravenous enzyme replacement therapy every two weeks for 52 weeks.
Who makes Infilbray?
The FDA granted the approval to Genzyme Corporation, a Sanofi Company, according to the agency's news release.
Sources
- FDA news release: FDA Approves First Drug to Treat Neurological Symptoms of Type 3 Gaucher Disease — fda.gov (2026-11-18). fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-
This is news, not medical advice. EMS clinicians: follow your local protocols and medical direction.


